Angiotensin 12 (1-9) Mechanisms, Clinical Applications, and

Angiotensin 1/2 (1-9): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Angiotensin 1/2 (1-9) is a bioactive peptide fragment derived from the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid homeostasis, and cardiovascular function. Angiotensin (1-9) is generated from angiotensin I by the action of angiotensin-converting enzyme 2 (ACE2), distinguishing it from the classical pathway that produces angiotensin II, a potent vasoconstrictor (Santos et al., 2013, Circulation Research). The peptide sequence of angiotensin (1-9) is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His, and it is increasingly recognized for its unique biological activities, including vasodilation, anti-fibrotic, and anti-inflammatory effects (Ocaranza & Jalil, 2012, Hypertension Research).

Mechanistically, angiotensin (1-9) exerts its effects primarily through the angiotensin type 2 receptor (AT2R), counteracting the deleterious actions of angiotensin II mediated by the angiotensin type 1 receptor (AT1R). This alternative RAS axis has been implicated in cardiovascular protection, tissue repair, and modulation of inflammatory responses (Ferreira et al., 2012, Peptides). The growing interest in angiotensin (1-9) stems from its potential to address limitations of current RAS-targeted therapies, such as ACE inhibitors and angiotensin receptor blockers (ARBs), by providing complementary or synergistic mechanisms of action.

Clinical Value and Applications
The clinical value of angiotensin (1-9) lies in its emerging role as a modulator of cardiovascular and renal pathophysiology. Unlike angiotensin II, which promotes vasoconstriction, sodium retention, fibrosis, and inflammation, angiotensin (1-9) has been shown to induce vasodilation, inhibit cardiac and vascular remodeling, and attenuate inflammatory responses (Ocaranza & Jalil, 2012). These properties position angiotensin (1-9) as a promising candidate for the treatment of hypertension, heart failure, myocardial infarction, and chronic kidney disease.

Preclinical studies have demonstrated that angiotensin (1-9) administration reduces cardiac hypertrophy and fibrosis in animal models of myocardial infarction, suggesting a cardioprotective effect independent of blood pressure reduction (Ferreira et al., 2012). Additionally, angiotensin (1-9) has been implicated in the regulation of endothelial function and prevention of atherosclerosis, further supporting its therapeutic potential in cardiovascular disease (Santos et al., 2013).

Beyond cardiovascular applications, angiotensin (1-9) may have utility in modulating inflammatory and fibrotic processes in other organ systems, including the lungs and kidneys. For example, recent investigations have explored its role in attenuating pulmonary fibrosis and renal injury, highlighting the broad therapeutic implications of this peptide (Barroso et al., 2017, Frontiers in Pharmacology).

[Related: y27632 inhibitor] Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, such as ACE inhibitors and ARBs, are effective in reducing morbidity and mortality in cardiovascular and renal diseases but are associated with several limitations. These include incomplete blockade of the RAS, compensatory upregulation of alternative pathways, and adverse effects such as hyperkalemia, cough, and angioedema (Burnier, 2019, European Heart Journal).

Angiotensin (1-9) addresses several of these challenges by engaging the protective arm of the RAS. Its mechanism of action via AT2R activation provides anti-fibrotic and anti-inflammatory effects without the vasoconstrictive and hypertrophic actions associated with AT1R stimulation. Moreover, angiotensin (1-9) may circumvent the compensatory increase in angiotensin II levels observed with chronic ACE inhibition, offering a more balanced modulation of the RAS (Ocaranza & Jalil, 2012).

Another significant pain point in current treatments is the limited efficacy in reversing established tissue fibrosis and remodeling. Angiotensin (1-9) has demonstrated the ability to attenuate and even reverse fibrotic changes in preclinical models, suggesting a potential advantage over conventional therapies (Ferreira et al., 2012).

Literature Review
A growing body of literature supports the biological and therapeutic relevance of angiotensin (1-9). Key studies include:

1. Santos et al. (2013, Circulation Research): This seminal review outlines the non-classical RAS axis, emphasizing the protective roles of angiotensin (1-7) and angiotensin (1-9). The authors highlight the anti-hypertrophic and anti-fibrotic effects of angiotensin (1-9) in cardiovascular disease models.

2. Ocaranza & Jalil (2012, Hypertension Research): This article discusses the pathophysiological significance of angiotensin (1-9) in cardiovascular remodeling, summarizing preclinical evidence for its cardioprotective actions.

3. Ferreira et al. (2012, Peptides): In this experimental study, angiotensin (1-9) administration in rats post-myocardial infarction resulted in reduced cardiac hypertrophy and fibrosis, supporting its therapeutic potential.

4. Barroso et al. (2017, Frontiers in Pharmacology): The authors investigate the effects of angiotensin (1-9) in a model of pulmonary fibrosis, demonstrating attenuation of fibrotic markers and improved lung function.

5. Benter et al. (2015, Journal of Cardiovascular Pharmacology): This study explores the vascular effects of angiotensin (1-9), showing improved endothelial function and reduced oxidative stress in hypertensive rats.

6. Burnier (2019, European Heart Journal): This review discusses the limitations of current RAS inhibitors and the need for novel therapeutic strategies, providing context for the development of angiotensin (1-9)-based interventions.

7. Chappell (2016, American Journal of Physiology-Heart and Circulatory Physiology): This review elaborates on the alternative RAS pathways, including the role of angiotensin (1-9) in cardiovascular homeostasis.

[Related: Non muscle myosin II ATPase inhibitor] Experimental Data and Results
Experimental evidence for the efficacy of angiotensin (1-9) is primarily derived from preclinical studies. In a rat model of myocardial infarction, Ferreira et al. (2012) administered angiotensin (1-9) via osmotic minipumps for four weeks post-infarction. The treated group exhibited significant reductions in left ventricular hypertrophy, interstitial fibrosis, and inflammatory cell infiltration compared to controls. These effects were attributed to AT2R activation, as co-administration of an AT2R antagonist abrogated the benefits.

Barroso et al. (2017) evaluated the anti-fibrotic effects of angiotensin (1-9) in a bleomycin-induced pulmonary fibrosis model. Mice treated with angiotensin (1-9) showed decreased collagen deposition, reduced expression of pro-fibrotic genes (TGF-β1, α-SMA), and improved lung compliance. These findings suggest a direct role for angiotensin (1-9) in modulating fibrotic pathways.

Benter et al. (2015) investigated the vascular actions of angiotensin (1-9) in spontaneously hypertensive rats. Chronic administration of the peptide led to improved endothelial-dependent vasodilation, reduced oxidative stress markers, and lower systolic blood pressure. The study also noted enhanced nitric oxide bioavailability, implicating endothelial nitric oxide synthase (eNOS) activation as a potential mechanism.

Collectively, these data support the hypothesis that angiotensin (1-9) exerts beneficial effects on cardiovascular and pulmonary tissues through anti-fibrotic, anti-inflammatory, and vasodilatory mechanisms. However, translation to human clinical studies remains limited, underscoring the need for further investigation.

Usage Guidelines and Best Practices
Angiotensin (1-9) is primarily utilized in research settings to elucidate the physiological and pathological roles of the alternative RAS axis. The peptide is typically administered via subcutaneous or intravenous routes in animal models, with dosing regimens ranging from 24 to 100 μg/kg/day depending on the experimental design (Ferreira et al., 2012; Barroso et al., 2017).

For in vitro studies, angiotensin (1-9) is applied to cultured cells at concentrations between 10 nM and 1 μM to assess signaling pathways, gene expression, and functional outcomes (Benter et al., 2015). It is essential to use high-purity, validated peptide preparations to ensure reproducibility and minimize confounding effects.

Best practices for experimental use include:
- Employing appropriate controls, such as vehicle-treated groups and receptor antagonists, to delineate specific mechanisms.< [Related: nitrocefin structure] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 26 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11581775